Company / PP&E (Net)
Apellis Pharmaceuticals, Inc. PP&E (Net) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.7M
FY2025
5-year range
$1.7M / $6.2M
FY2021-FY2025
Trend
-42.1%
vs FY2024
Sector context
#140 of 193
Health Care
What the data says
At $2M, Apellis Pharmaceuticals, Inc.'s pp&e (net) ranks #140 of 193 in the Health Care sector. PP&E (Net) has declined for 5 consecutive years, from $7M in FY2020 to $2M in FY2025.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of -24.1%.
Declined from $4M to $2M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -34.7%
- 5-Year CAGR
- -24.1%
- 10-Year CAGR
- -
Sector benchmark
#140 of 193 in Health CareTop 73% of 193This company $1.7M Sector average $777.6M
▼
-99.8% below sector average
Key checks
Key Insights
- Apellis Pharmaceuticals, Inc.'s pp&e (net) has declined for 5 consecutive years.
- 5-year CAGR of -24.1%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 42.1% year-over-year.
- Ranks #140 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.7M | -42.1% |
| FY2024 | $3.0M | -32.1% |
| FY2023 | $4.3M | -29.3% |
| FY2022 | $6.1M | -0.5% |
| FY2021 | $6.2M | -9.2% |
| FY2020 | $6.8M | +311.1% |
| FY2019 | $1.7M | +69.2% |
| FY2018 | $977.9K | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026